Abstract 52P
Background
We evaluated the relationship between 18F-FDG uptake and mitochondrial activity in cancer cells and investigated the prognostic implications thereof in patients with invasive ductal carcinoma of the breast (IDCB).
Methods
In total, 150 consecutive patients with IDCB who underwent preoperative 18F-FDG PET/CT followed by curative surgical resection were retrospectively enrolled. Mitochondrial activity of cancer cells was assessed based on translocase of outer mitochondrial membrane 20 (TOMM20) expression and cytochrome C oxidase (COX) activity. Pearson’s correlation analysis was used to assess the relationship between SUVmax of the primary tumour (pSUVmax) and mitochondrial activity. Clinicopathological factors, including pSUVmax, histological grade, expression of ER, PR, HER2, and TOMM20, and COX activity, were assessed for prediction of progression-free survival (PFS). The Kaplan–Meier method and Cox proportional hazards model were used for the survival analysis.
Results
Sixteen of the 150 subjects (10.7%) showed progression during the follow-up period. pSUVmax correlated significantly and positively with TOMM20 expression and COX activity. Univariate analysis revealed that pSUVmax, TOMM20 expression, COX activity, ER and PR status, and histologic grade were significantly associated with PFS. Multivariate analysis revealed a significant difference in pSUVmax (HR, 4.50; 95% CI, 1.43–14.17; P = 0.010).
Conclusions
There was a significant positive correlation between 18F-FDG uptake and mitochondrial activity of cancer cells in patients with IDCB. Increased 18F-FDG uptake and mitochondrial activity were significantly associated with a shorter PFS. Therefore, assessment of preoperative 18F-FDG uptake and post-surgical mitochondrial activity in patients with IDCB could be used as marker for prediction of PFS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Choi Byung Wook (Daegu Catholic University Medical Center).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
259P - The BOT patients fail to benefit from surgical staging procedures in prognosis and fertility outcomes: A retrospective analysis
Presenter: Li Na
Session: Poster display session
Resources:
Abstract
260P - Malignant ovarian germ cell tumours (MOGCT): Treatment results of 149 pts
Presenter: Dzhennet Chekini
Session: Poster display session
Resources:
Abstract
261P - Ovarian germ cell tumours - challenges and outcomes from a tertiary care centre in South India
Presenter: Vishnu Sreedath
Session: Poster display session
Resources:
Abstract
262P - Gestational trophoblastic tumours: Experience of the medical oncology department Hassan II University Hospital-Morocco about 29 cases
Presenter: Karima Oualla
Session: Poster display session
Resources:
Abstract
263TiP - ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
264TiP - ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
265TiP - KEYNOTE-826: A phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Presenter: Keiichi Fujiwara
Session: Poster display session
Resources:
Abstract
271P - Comparison between CHOP like regimens and DAEPOCH with or without Rituximab in adult high grade B cell lymphoma NOS; A retrospective study from a tertiary cancer hospital in South India
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
272P - Melatonin increases the chemosensitivity of diffuse large Bell lymphoma cells to Epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway
Presenter: Xiuhua Sun
Session: Poster display session
Resources:
Abstract
273P - MALT1- A20 and NF-κB expression pattern in patients with non-Hodgkin lymphomas
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract